Evaluation of FGFR2b in context of relevant biomarkers supports potential combination of anti-FGFR2b with anti-PD-(L)1 therapy in gastric cancer

被引：2
|
作者：
Sharma, Khushboo [1 ]
Schmidt, Maike [1 ]
Hestir, Kevin [1 ]
Mendoza, Nerissa [1 ]
Powers, Janine [2 ]
Hnatyszyn, James [1 ]
机构：
[1] Five Prime Therapeut, San Francisco, CA USA
[2] Nurix Inc, San Francisco, CA USA
来源：
MOLECULAR CANCER THERAPEUTICS | 2019年 / 18卷 / 12期
关键词：
D O I：
10.1158/1535-7163.TARG-19-A033
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A033
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Preclinical characterization of bemarituzumab, an anti-FGFR2b antibody for the treatment of cancer
    Xiang, Hong
    Chan, Abigael G.
    Ahene, Ago
    Bellovin, David I.
    Deng, Rong
    Hsu, Amy W.
    Jeffry, Ursula
    Palencia, Servando
    Powers, Janine
    Zanghi, James
    Collins, Helen
    MABS, 2021, 13 (01)
  • [2] Development of GB2102, a novel and highly differentiated anti-FGFR2b antibody for the treatment of gastric cancer
    Zhou, Tiantian
    Du, Qinglin
    Yang, Xueyan
    Peng, Fei
    Li, James
    Han, Shuhua
    CANCER RESEARCH, 2022, 82 (12)
  • [3] Expression of FGFR2b in gastric cancer as measured by immunohistochemistry with a highly specific monoclonal antibody
    Deshpande, Amit M.
    Palencia, Servando
    Bellovin, David I.
    Gemo, Abigael T.
    Giese, Tina
    Stohr, Bradley
    Pierce, Kristen L.
    Los, Gerrit
    CANCER RESEARCH, 2014, 74 (19)
  • [4] Combination therapy for pancreatic cancer: anti-PD-(L)1-based strategy
    Lingyue Liu
    Xing Huang
    Fukang Shi
    Jinyuan Song
    Chengxiang Guo
    Jiaqi Yang
    Tingbo Liang
    Xueli Bai
    Journal of Experimental & Clinical Cancer Research, 41
  • [5] Combination therapy for pancreatic cancer: anti-PD-(L)1-based strategy
    Liu, Lingyue
    Huang, Xing
    Shi, Fukang
    Song, Jinyuan
    Guo, Chengxiang
    Yang, Jiaqi
    Liang, Tingbo
    Bai, Xueli
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2022, 41 (01)
  • [6] Covariate effects and population pharmacokinetic analysis of the anti-FGFR2b antibody bemarituzumab in patients from phase 1 to phase 2 trials
    Xiang, Hong
    Liu, Lucy
    Gao, Yuying
    Ahene, Ago
    Collins, Helen
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2021, 88 (05) : 899 - 910
  • [7] Covariate effects and population pharmacokinetic analysis of the anti-FGFR2b antibody bemarituzumab in patients from phase 1 to phase 2 trials
    Hong Xiang
    Lucy Liu
    Yuying Gao
    Ago Ahene
    Helen Collins
    Cancer Chemotherapy and Pharmacology, 2021, 88 : 899 - 910
  • [8] Updated antitumor activity and safety of FPA144, an ADCC-enhanced, FGFR2b isoform-specific monoclonal antibody, in patients with FGFR2b+gastric cancer.
    Catenacci, Daniel V. T.
    Rha, Sun Young
    Bang, Yung-Jue
    Wainberg, Zev A.
    Chao, Joseph
    Lee, Keun Wook
    Korn, Wolfgang Michael
    Kim, Yeul Hong
    Song, Eun-Kee
    Chiu, Chang -Fang
    Yen, Chia-Jui
    Berlin, Jordan
    Kim, Jin-Soo
    Sikorski, Robert S.
    Collins, Helen
    Clark, Lee
    Inamdar, Sandeep P.
    Zhang, Charlie
    Lee, Jeeyun
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [9] Antitumor activity and safety of FPA144, an ADCC-enhanced, FGFR2b isoform-selective monoclonal antibody, in patients with FGFR2b+gastric cancer and advanced solid tumors.
    Lee, Jeeyun
    Bendell, Johanna C.
    Rha, Sun Young
    Bang, Yung-Jue
    Clark, Lee
    Xiang, Hong
    Pierce, Kristen L.
    Krishnan, Kartik
    Sikorski, Robert S.
    Rasco, Drew W.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [10] Exploration of serum biomarkers in dogs with malignant melanoma receiving anti-PD-L1 therapy and potential of COX-2 inhibition for combination therapy
    Naoya Maekawa
    Satoru Konnai
    Yumie Asano
    Yamato Sajiki
    Tatsuya Deguchi
    Tomohiro Okagawa
    Kei Watari
    Hiroto Takeuchi
    Satoshi Takagi
    Kenji Hosoya
    Sangho Kim
    Hiroshi Ohta
    Yukinari Kato
    Yasuhiko Suzuki
    Shiro Murata
    Kazuhiko Ohashi
    Scientific Reports, 12
12345